Table 3.

Three-year adjusted probabilities of disease-free survival, relapse, nonrelapse mortality, overall survival, chronic GVHD, and day 100 acute grade II to IV acute GVHD

OutcomeMyeloablative regimen (95% CI), %Reduced-intensity regimen (95% CI), %P
Disease-free survival    
 Age, 18-54 y 47 (41-52) 35 (29-41) .009 
 Age, 55-70 y 40 (32-49) 33 (28-38) .15 
Relapse    
 Age, 18-54 y 38 (32-43) 51 (44-57) .003 
 Age, 55-70 y 34 (25-43) 46 (41-51) .03 
Nonrelapse mortality    
 Age, 18-54 y 18 (14-22) 17 (12-22) .81 
 Age, 55-70 y 30 (22-38) 24 (19-30) .26 
Overall survival    
 Age, 18-54 y 54 (49-60) 49 (42-55) .19 
 Age, 55-70 y 42 (33-50) 38 (33-43) .48 
Acute grade II-IV GVHD    
 Age, 18-54 y 24 (20-28) 20 (15-25) .23 
 Age, 55-70 y 23 (16-30) 20 (17-24) .52 
Chronic GVHD    
 Age, 18-54 y 38 (29-47) 38 (33-43) .97 
 Age, 55-70 y 26 (19-34) 28 (23-32) .75 
OutcomeMyeloablative regimen (95% CI), %Reduced-intensity regimen (95% CI), %P
Disease-free survival    
 Age, 18-54 y 47 (41-52) 35 (29-41) .009 
 Age, 55-70 y 40 (32-49) 33 (28-38) .15 
Relapse    
 Age, 18-54 y 38 (32-43) 51 (44-57) .003 
 Age, 55-70 y 34 (25-43) 46 (41-51) .03 
Nonrelapse mortality    
 Age, 18-54 y 18 (14-22) 17 (12-22) .81 
 Age, 55-70 y 30 (22-38) 24 (19-30) .26 
Overall survival    
 Age, 18-54 y 54 (49-60) 49 (42-55) .19 
 Age, 55-70 y 42 (33-50) 38 (33-43) .48 
Acute grade II-IV GVHD    
 Age, 18-54 y 24 (20-28) 20 (15-25) .23 
 Age, 55-70 y 23 (16-30) 20 (17-24) .52 
Chronic GVHD    
 Age, 18-54 y 38 (29-47) 38 (33-43) .97 
 Age, 55-70 y 26 (19-34) 28 (23-32) .75 

or Create an Account

Close Modal
Close Modal